FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. 20549 | |
|-------------|------------|--|

| Check this box if no longer subject |
|-------------------------------------|
| to Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Landau Jeffrey B ——————————————————————————————————— | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>CytomX Therapeutics</u> , <u>Inc.</u> [CTMX] | | | | | | | | | 5. Relationship of Repo (Check all applicable) Director V Officer (give till | | | 10% Othe | Owner er (specify | | |
|--|---|--|--|------------|--|--|------------------|---|-------------------------|---|------------------------|---|---|---|--|--|---|--|-------------------------------------|--|
| (Last) (First) (Middle) C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/19/2022 | | | | | | | | | Chief Business Officer | | | | | | |
| (Street) SOUTH SAN FRANCISCO CA 94080 | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (Sta | , , | ľip) | | | | | | | | | | | | | | | | | |
| Table I - Non-Do 1. Title of Security (Instr. 3) 2. Tran Date (Month | | | action | n 'ear) | 2A. Deemed Execution Date, | | nte, | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired Disposed Of (D) (Instr. | | d (A) or | | 5. Amount of Securities Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | Code V | | Amount | (A) or (D) | (A) or (D) Price | | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | |
| Common | Stock | | | | | | | | | | | | | | 4,5 | 00 | | I | Fidelity Traditional IRA | |
| Common | Common Stock | | | | | | | | | | | | | | 3,180 | | I | | Schwab ROTH IRA | |
| Common | Stock | | 07/1 | 9/202 | 22 | | | | A ⁽¹⁾ | | 11,250 | A | \$0 | | 34,931(2)(3) | | D | | | |
| Common Stock 07/20/2022 | | | 22 | | | | S ⁽⁴⁾ | | 4,206 | D | \$1.42 | 222 30,725(2) | | 25(2) | D | | | | | |
| | | Tal | ole II - Deri (e.g | | | | | | | | posed of, convertil | | | | / Owned | d | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Da if any (Month/Day/Y | te, | 4. Trans | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 6. Da Expi | ate Exe | ercisable and | 7. Titl Amou Secur Unde Deriv | e and int of rities rlying ative rity (Insti | 8 0 | 3. Price of Derivative Security Instr. 5) | 9. Numb derivativ Securitie Benefici Owned Followir Reporte Transac (Instr. 4) | ve es ially ng d tion(s) | 10. Ownersi Form: Direct (I or Indire (I) (Instr. | Beneficial Ownership oct (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exer | rcisable | Expiration Date | Title | Amoun or Numbe of Shares | r | | | | | | |

Explanation of Responses:

- 1. Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
- 2. Includes 16,274 restricted stock units.
- 3. Reflects the adjusted total which includes the purchase of 5,040 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022.
- 4. The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.

/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B 07/21/2022 Landau

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.